Growing Revenue Streams Cubist Pharmaceuticals has demonstrated strong revenue growth with over one billion dollars in worldwide sales for its blockbuster drug CUBICIN and a 22 percent increase in Q4 2013, indicating a solid market position and expanding sales opportunities in the antibiotics and infectious disease segments.

Pipeline Expansion The company's focus on developing advanced antibiotics such as ceftolozane/tazobactam and tedizolid phosphate presents significant opportunities to target hospitals and healthcare providers seeking new treatments for resistant Gram-negative and Gram-positive infections.

Market Focus on CDAD With a large and growing market linked to Clostridium difficile associated diarrhea, Cubist's re-launch of DIFICID and ongoing development of surotomycin positions sales teams to target healthcare facilities managing this urgent public health threat.

Regulatory Milestones Pending FDA and EMA approvals for key products like tedizolid phosphate and ceftolozane/tazobactam could open new revenue channels, offering opportunities for strategic partnerships, licensing deals, or targeted marketing efforts once products reach the market.

Strategic Market Positioning Cubist’s focus on advancing drugs for serious infections and its investments in innovative therapies for resistant bacteria highlight the potential to build long-term collaborations with healthcare providers and institutions focused on combating antimicrobial resistance.